다시 보는 알츠하이머병의 아밀로이드 가설

키워드

참고문헌 (116)

1. Goate A, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease", Nature, 349, pp.704~706 (1991)
2. Hardy JA, "Alzheimer’s disease : the amyloid cascade hypothesis", Science, 256, pp.184~185 (1992)
3. Salloway S, "Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease", New England Journal of Medicine, 370, pp.322~333 (2014)
4. Doody RS, "Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease", New England Journal of Medicine, 370, pp.311~321 (2014)
5. Doody RS, "A Phase 3 Trial of Semagacestat for Treatment of Alzheimer’s Disease", New England Journal of Medicine, 369, pp.341~350 (2013)
6. Hardy J, "The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
7. Selkoe DJ, "Alzheimer’s disease : molecular understanding predicts amyloid-based therapeutics", Annu Rev Pharmacol Toxicol, 43, pp.545~584 (2003)
8. Yan R, "Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity", Nature, 402, pp.533~537 (1999)
9. Edbauer D, "Reconstitution of gamma-secretase activity", Nat Cell Biol, 5, pp.486~488 (2003)
10. Selkoe D, "Notch and Presenilin : regulated intramembrane proteolysis links development and degeneration", Annu Rev Neurosci, 26, pp.565~597 (2003)
11. Iwatsubo T, "Visualization of A beta 42(43)and A beta 40 in senile plaques with end-specific A beta monoclonals : evidence that an initially deposited species is A beta 42(43)", Neuron, 13, pp.45~53 (1994)
12. Verdile G, "The role of beta amyloid in Alzheimer’s disease: still a cause of everything or the only one who got caught?", Pharmacol Res, 50, pp.397~409 (2004)
13. Lichtenthaler SF, "alpha-secretase in Alzheimer’s disease: molecular identity, regulation and therapeutic potential", J Neurochem, 116, pp.10~21 (2011)
14. Selkoe DJ, "Alzheimer’s disease: genotypes, phenotypes, and treatments", Science, 275, pp.630~631 (1997)
15. Karran E, "The amyloid cascade hypothesis for Alzheimer’s disease : an appraisal for the development of therapeutics", Nat Rev Drug Discov, 10, pp.698~712 (2011)
16. Zigman WB, "Alzheimer’s disease in Down syndrome : neurobiology and risk", Ment Retard Dev Disabil Res Rev, 13, pp.237~246 (2007)
17. Kayed R, "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis", Science, 300, pp.486~489 (2003)
18. Cleary JP, "Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function", Nat Neurosci, 8, pp.79~84 (2005)
19. Shankar GM, "Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory", Nat Med, 14, pp.837~842 (2008)
20. Garai K, "Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta", Proc Natl Acad Sci U S A, 110, pp.3321~3326 (2013)
21. Tokuda T, "Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides", Biochem J, 2, pp.359~365 (2000)
22. Holtzman DM, "Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease", Proc Natl Acad Sci U S A, 97, pp.2892~2897 (2000)
23. DeMattos RB, "Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease", Proc Natl Acad Sci U S A, 99, pp.10843~10848 (2002)
24. Selkoe DJ, "Clearing the brain’s amyloid cobwebs", Neuron, 32, pp.177~180 (2001)
25. Mawuenyega KG, "Decreased clearance of CNS beta-amyloid in Alzheimer’s disease", Science, 330, pp.1774~ (2010)
26. Saido T, "Proteolytic degradation of amyloid beta-protein", Cold Spring Harb Perspect Med, 2, pp.a006379~ (2012)
27. Farris W, "Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy", Am J Pathol, 171, pp.241~251 (2007)
28. Leissring MA, "Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death", Neuron, 40, pp.1087~1093 (2003)
29. Iwata N, "Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain", J Neurosci, 24, pp.991~998 (2004)
30. Hemming ML, "Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease", PLoS Med, 4, pp.e262~ (2007)
31. Shibata M, "Clearance of Alzheimer’s amyloidss(1-40)peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier", J Clin Invest, 106, pp.1489~1499 (2000)
32. Bell RD, "Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system", J Cereb Blood Flow Metab, 27, pp.909~918 (2007)
33. Zlokovic BV, "Cerebrovascular effects of apolipoprotein E : implications for Alzheimer disease", JAMA Neurol, 70, pp.440~444 (2013)
34. Sagare AP, "Low-density lipoprotein receptor-related protein 1 : a physiological Abeta homeostatic mechanism with multiple therapeutic opportunities", Pharmacol Ther, 136, pp.94~105 (2012)
35. Armstrong RA, "The spatial patterns of plaques and tangles in Alzheimer’s disease do not support the ‘cascade hypothesis’", Dementia, 4, pp.16~20 (1993)
36. Duyckaerts C, "Looking for the link between plaques and tangles", Neurobiol Aging, 25, pp.735~739 (2004)
37. Armstrong RA, "Plaques and tangles and the pathogenesis of Alzheimer’s disease", Folia Neuropathol, 44, pp.1~11 (2006)
38. Busciglio J, "beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding", Neuron, 14, pp.879~888 (1995)
39. Perez M, "Interaction of Alzheimer’s disease amyloid beta peptide fragment 25-35 with tau protein, and with a tau peptide containing the microtubule binding domain", J Alzheimers Dis, 6, pp.461~467 (2004)
40. McGeer PL, "The possible role of complement activation in Alzheimer disease", Trends Mol Med, 8, pp.519~523 (2002)
41. Okello A, "Conversion of amyloid positive and negative MCI to AD over 3 years : an 11C-PIB PET study", Neurology, 73, pp.754~760 (2009)
42. Okello A, "Microglial activation and amyloid deposition in mild cognitive impairment : a PET study", Neurology, 72, pp.56~62 (2009)
43. Rogers J, "Complement activation by beta-amyloid in Alzheimer disease", Proc Natl Acad Sci USA, 89, pp.10016~10020 (1992)
44. Rogers J, "Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer’s disease", Res Immunol, 143, pp.624~630 (1992)
45. Fiala M, "Phagocytosis of amyloid-beta and inflammation : two faces of innate immunity in Alzheimer’s disease", J Alzheimers Dis, 11, pp.457~463 (2007)
46. Medeiros R, "Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease : relevance for the behavioral and synaptic deficits induced by amyloid beta protein", J Neurosci, 27, pp.5394~5404 (2007)
47. Town T, "Blocking TGF-beta-Smad2", 3 innate immune signaling mitigates Alzheimer-like pathology, 2008, pp.14, 681~687
48. Tesseur I, "Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology", J Clin Invest, 116, pp.3060~3069 (2006)
49. Notkola IL, "Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease", Neuroepidemiology, 17, pp.14~20 (1998)
50. Wolozin B, "Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors", Arch Neurol, 57, pp.1439~1443 (2000)
51. Kojro E, "Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10", Proc Natl Acad Sci USA, 98, pp.5815~5820 (2001)
52. Wahrle S, "Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains", Neurobiol Dis, 9, pp.11~23 (2002)
53. Ehehalt R, "Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts", J Cell Biol, 160, pp.113~123 (2003)
54. Sawamura N, "Modulation of amyloid precursor protein cleavage by cellular sphingolipids", J Biol Chem, 279, pp.11984~11991 (2004)
55. Osenkowski P, "Direct and potent regulation of gamma-secretase by its lipid microenvironment", J Biol Chem, 283, pp.22529~22540 (2008)
56. Yoon IS, "Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway", FASEB J, 21, pp.2742~2752 (2007)
57. Puglielli L, "Acyl-coenzyme A : cholesterol acyltransferase modulates the generation of the amyloid beta-peptide", Nat Cell Biol, 3, pp.905~912 (2001)
58. Huttunen HJ, "Knockdown of ACAT-1 reduces amyloidogenic processing of APP", FEBS Lett, 581, pp.1688~1692 (2007)
59. Huttunen HJ, "Inhibition of acyl-coenzyme A : cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway", FASEB J, 23, pp.3819~3828 (2009)
60. Landreth G, "PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease", Neurotherapeutics, 5, pp.481~489 (2008)
61. Gold M, "Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study", Dement Geriatr Cogn Disord, 30, pp.131~146 (2010)
62. Wolfe MS, "gamma-Secretase inhibitors and modulators for Alzheimer’s disease", J Neurochem, 120(Suppl 1), pp.89~98 (2012)
63. Doody RS, "A phase 3 trial of semagacestat for treatment of Alzheimer’s disease", N Engl J Med, 369, pp.341~350 (2013)
64. Chavez-Gutierrez L, "The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease", EMBO J, 31, pp.2261~2274 (2012)
65. Martone RL, "Begacestat(GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease", J Pharmacol Exp Ther, 331, pp.598~608 (2009)
66. Imbimbo BP, "Therapeutic potential of gamma-secretase inhibitors and modulators", Curr Top Med Chem, 8, pp.54~61 (2008)
67. Lanz TA, "Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014", J Pharmacol Exp Ther, 334, pp.269~277 (2010)
68. Green RC, "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease : a randomized controlled trial", JAMA, 302, pp.2557~2564 (2009)
69. Imbimbo BP, "CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer’s disease", Br J Pharmacol, 156, pp.982~993 (2009)
70. Griffiths HH, "Emerging and potential therapies for Alzheimer’s disease", Expert Opin Ther Targets, 12, pp.693~704 (2008)
71. Marcade M, "Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing", J Neurochem, 106, pp.392~404 (2008)
72. Vellas B, "EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study", Curr Alzheimer Res, 8, pp.203~212 (2011)
73. Etcheberrigaray R, "Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice", Proc Natl Acad Sci USA, 101, pp.11141~11146 (2004)
74. Snow AD, "Exebryl-1: A novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer’s disease", Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 5, pp.418~ (2009)
75. Aisen PS, "A Phase II study targeting amyloidbeta with 3APS in mild-to-moderate Alzheimer disease", Neurology, 67, pp.1757~1763 (2006)
76. Aisen PS, "Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study(the Alphase Study)", Arch Med Sci, 7, pp.102~111 (2011)
77. Faux NG, "PBT2 rapidly improves cognition in Alzheimer’s Disease : additional phase II analyses", J Alzheimers Dis, 20, pp.509~516 (2010)
78. Lannfelt L, "Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial", Lancet Neurol, 7, pp.779~786 (2008)
79. McLaurin J, "Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model", Nat Med, 12, pp.801~808 (2006)
80. Salloway S, "A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease", Neurology, 77, pp.1253~1262 (2011)
81. Mandel SA, "Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols : special reference to epigallocatechin gallate(EGCG)", J Alzheimers Dis, 15, pp.211~222 (2008)
82. Lannfelt L, "Amyloid-ß-directed immunotherapy for Alzheimer’s disease", Journal of Internal Medicine, 275, pp.284~295 (2014)
83. Bard F, "Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology", Proc Natl Acad Sci USA, 100, pp.2023~2028 (2003)
84. Bard F, "Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease", Nat Med, 6, pp.916~919 (2000)
85. Buttini M, "Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease", J Neurosci, 25, pp.9096~9101 (2005)
86. Zago W, "Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific", J Neurosci, 32, pp.2696~2702 (2012)
87. Sperling R, "Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab : a retrospective analysis", Lancet Neurol, 11, pp.241~249 (2012)
88. Salloway S, "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease", Neurology, 73, pp.2061~2070 (2009)
89. Farlow M, "Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease", Alzheimers Dement, 8, pp.261~271 (2012)
90. Doody RS, "Alzheimer’s Disease Cooperative Study Data A, Publication C. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease", N Engl J Med, 370, pp.1460~ (2014)
91. Bohrmann B, "Gantenerumab : a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta", J Alzheimers Dis, 28, pp.49~69 (2012)
92. Ostrowitzki S, "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab", Arch Neurol, 69, pp.198~207 (2012)
93. Panza F, "Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease", Expert Rev Neurother, pp.1~14 (2014)
94. Adolfsson O, "An effector-reduced anti-beta-amyloid(Abeta)antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta", J Neurosci, 32, pp.9677~9689 (2012)
95. Frisoni GB, "Primary or secondary prevention for AD: who cares?", Lancet Neurol, 11(7), pp.567~ (2012)
96. Lannfelt L, "Perspectives on future Alzheimer therapies : amyloid-beta protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer’s disease", Alzheimers Res Ther, 6, pp.16~ (2014)
97. Schenk D., "Amyloid-beta immunotherapy for Alzheimer’s disease : the end of the beginning", Nat Rev Neurosci, 3, pp.824~828 (2002)
98. Gilman S, "Clinical effects of Abeta immunization(AN1792)in patients with AD in an interrupted trial", Neurology, 64, pp.1553~1562 (2005)
99. Nicoll JA, "Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : a case report", Nat Med, 9, pp.448~452 (2003)
100. Fox NC, "Effects of Abeta immunization(AN1792)on MRI measures of cerebral volume in Alzheimer disease", Neurology, 64, pp.1563~1572 (2005)
101. Winblad B, "Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study", Lancet Neurol, 11, pp.597~604 (2012)
102. Ryan JM, "Anti-amyloid-beta immunotherapy in Alzheimer’s disease : ACC-001 clinical trials are ongoing", J Alzheimers Dis, 17, pp.243~ (2009)
103. Schneeberger A, "Development of AFFITOPE vaccines for Alzheimer’s disease(AD)--from concept to clinical testing", J Nutr Health Aging, 13, pp.264~267 (2009)
104. Rabinovici GD, "Amyloid imaging in aging and dementia : testing the amyloid hypothesis in vivo", Behav Neurol, 21, pp.117~128 (2009)
105. Rowe CC, "Imaging beta-amyloid burden in aging and dementia", Neurology, 68, pp.1718~1725 (2007)
106. Rodrigue KM, "beta-Amyloid burden in healthy aging : regional distribution and cognitive consequences", Neurology, 78, pp.387~395 (2012)
107. Holmes C, "Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial", Lancet, 372, pp.216~223 (2008)
108. Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
109. Braak H, "Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry", Acta Neuropathol, 112, pp.389~404 (2006)
110. Gomez-Isla T, "Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease", Ann Neurol, 41, pp.17~24 (1997)
111. Roberson ED, "Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model", Science, 316, pp.750~754 (2007)
112. Holmes C, "The clinical phenotype of familial and sporadic late onset Alzheimer’s disease", Int J Geriatr Psychiatry, 17, pp.146~149 (2002)
113. Godbolt AK, "The natural history of Alzheimer disease : a longitudinal presymptomatic and symptomatic study of a familial cohort", Arch Neurol, 61, pp.1743~1748 (2004)
114. Irizarry MC, "APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1", J Neuropathol Exp Neurol, 56, pp.965~973 (1997)
115. Schaeffer EL, "Insights into Alzheimer disease pathogenesis from studies in transgenic animal models", Clinics, 66(Suppl 1), pp.45~54 (2011)
116. Schwab C, "Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease", Exp Neurol, 188, pp.52~64 (2004)

관련 논문AI추천